This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Cyclic and bicyclic peptides offer better stability and bioavailability than linear peptides while keeping the ability to block protein-protein interactions that small molecules cannot reach.
Why it matters
Protein-protein interactions drive many diseases but are hard to drug. Cyclic peptides fill a gap between small molecules and large biologics as a new class of therapeutics.
The numbers in context
N/A (review of design methodologies)
How the study worked
Narrative review of recent literature on macrocyclic and bicyclic peptide design, including computational, structure-guided, and phage display approaches.
Who was studied
N/A (review of peptide chemistry and drug design)
What this study cannot tell us
Narrative review without systematic methodology. Focuses on design principles rather than clinical outcomes. May not cover all recent developments equally.
Read the original research
Rational design of cyclic peptides, with an emphasis on bicyclic peptides.
Current opinion in structural biology, 92, 103025
Citation
Rowland, Catherine E; Bezerra, Gustavo Arruda; Skynner, Michael J. (2025). Rational design of cyclic peptides, with an emphasis on bicyclic peptides.. Current opinion in structural biology, 92, 103025. https://doi.org/10.1016/j.sbi.2025.103025